KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accounts Payables (2018 - 2025)

Vir Biotechnology's Accounts Payables history spans 8 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 92.93% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 92.93%, while the annual FY2025 figure was $9.8 million, 92.93% up from the prior year.
  • Accounts Payables for Q4 2025 was $9.8 million at Vir Biotechnology, up from $6.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $12.4 million in Q2 2023 and bottomed at $2.7 million in Q3 2022.
  • The 5-year median for Accounts Payables is $6.7 million (2021), against an average of $7.4 million.
  • The largest annual shift saw Accounts Payables plummeted 80.28% in 2021 before it skyrocketed 196.0% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $6.5 million in 2021, then dropped by 1.52% to $6.4 million in 2022, then dropped by 1.37% to $6.3 million in 2023, then decreased by 19.78% to $5.1 million in 2024, then skyrocketed by 92.93% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Accounts Payables are $9.8 million (Q4 2025), $6.8 million (Q3 2025), and $12.2 million (Q2 2025).